Torisel 25 mg (Temsirolimus SOLUTION) 25 MG

Temsirolimus 25 mg is an intravenous solution used for specific medical conditions. This medication, part of the Torisel brand, is manufactured by Pfizer Canada ULC and is designed for targeted therapeutic use.

Strength

25 MG

Pack Size

1.2ML + DILUENT 1.8ML

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Temsirolimus 25 mg is primarily used in the management of certain types of cancer. This solution is administered intravenously and is often prescribed for conditions where targeted therapy is required. Patients and healthcare providers typically discuss what Temsirolimus is used for based on individual health needs and treatment plans.

Side Effects

Common effects of Temsirolimus 25 mg may include reactions at the injection site, fatigue, and gastrointestinal issues. Individual responses can vary, and it is important to monitor for any unusual symptoms. Always consult a healthcare professional for personalized advice.

Precautions & Warnings

Temsirolimus 25 mg should be handled with care, following the instructions provided by a healthcare professional. It is important to store and administer this solution as directed to ensure safety and effectiveness. Patients should inform their healthcare provider about any existing medical conditions or medications they are taking.

Avoid Interactions

Temsirolimus 25 mg may interact with certain medications, including those that affect the immune system or other cancer treatments. It is advisable to discuss potential interactions with a healthcare provider, especially when combining with other therapies. Always follow professional medical advice regarding drug interactions.

Frequently Asked Questions

Temsirolimus 25 mg is used in the treatment of certain types of cancer, typically administered intravenously.

Temsirolimus 25 mg is administered intravenously, usually by a healthcare professional in a clinical setting.

Common side effects may include reactions at the injection site, fatigue, and gastrointestinal issues.

Potential interactions with other medications should be discussed with a healthcare provider.

Temsirolimus 25 mg should be stored as directed by the healthcare provider or pharmacist.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.